Available data indicate that vaccination with MMR has not been associated with severe or unusual adverse reactions in HIV-infected persons who are not severely immunosuppressed, although antibody responses have been variable.
A family history of congenital or hereditary immunodeficiency in first-degree relatives e. Receipt of specific antiviral drugs e. These drugs should be avoided for 14 days after vaccination. Simultaneous use of aspirin or aspirin-containing products is a precaution for MMRV vaccine due to the varicella component.
The manufacturer recommends that vaccine recipients avoid the use of salicylates for 6 weeks after receiving MMRV vaccine because of the association between aspirin use and Reye syndrome following chickenpox. A personal or family i. Children with a personal or family history of seizures of any etiology should ideally be vaccinated with separate MMR and VAR vaccines because the risks for using MMRV vaccine in this group of children generally outweigh the benefits.
MMR vaccine may be administered to egg-allergic persons without prior routine skin testing or the use of special protocols. The effect of the administration of antibody-containing blood products e.
Because of the potential inhibition of the response to vaccination by passively transferred antibodies, neither MMR vaccine nor MMRV vaccine nor VAR vaccine should be administered for 3 to 11 months after receipt of antibody-containing blood products. The interval between the antibody-containing blood product and receipt of MMR or MMRV vaccine is determined by the type of product administered.
Antibody-containing products should not be given for 2 weeks following vaccination unless the benefits exceed those of the vaccine. In such cases, vaccine recipients should either be revaccinated later at the appropriate intervals ranging 3 to 11 months or tested for immunity and revaccinated if seronegative. Measles vaccine and possibly mumps, rubella, and varicella vaccines may transiently suppress the response to tuberculin skin test TST in a person infected with Mycobacterium tuberculosis.
TST and measles-containing vaccine may be administered at the same visit if necessary. Simultaneously administering TST and measles-containing vaccine does not interfere with reading the TST result at 48 to 72 hours and ensures that the person has received measles vaccine. If the measles-containing vaccine has been administered recently, TST screening should be delayed for at least 4 weeks after vaccination.
If a pregnant woman inadvertently receives MMR or MMRV vaccine, termination of pregnancy is not recommended because the risk to the fetus appears to be extremely low. Instead, individual counseling for these women is recommended.
Data from susceptible women who received rubella vaccine showed no evidence of CRS in offspring. Studies conducted in six Latin American countries showed a negligible or absent risk for CRS after administration of rubella vaccine shortly before or during pregnancy.
Of the 1, susceptible pregnant women followed, 70 3. The experts determined that evidence supports a causal relation between MMR vaccination and anaphylaxis, febrile seizures, thrombocytopenic purpura, transient arthralgia, and measles inclusion body encephalitis in persons with demonstrated immunodeficiencies. Most adverse events reported following MMR vaccination such as fever and rash are attributable to the measles component. Most persons with fever do not have other symptoms.
MMR vaccine is associated with a very small risk of febrile seizures; approximately one case for every 3, to 4, doses of MMR vaccine administered. The febrile seizures typically occur 6 to 14 days after vaccination and do not appear to be associated with any long-term sequelae.
Children with a personal or family history of febrile seizures or family history of epilepsy might be at increased risk for febrile seizures after MMR vaccination. Allergic reactions following the administration of MMR vaccine are rare. Most of these are minor and consist of a wheal and flare or urticaria at the injection site. Immediate, anaphylactic reactions to MMR vaccine occur in 1. Rarely, MMR vaccine may cause thrombocytopenia within two months after vaccination.
The clinical course of these cases is usually transient and benign, although hemorrhage occurs rarely. Based on case reports, the risk for MMR vaccine-associated thrombocytopenia may be higher for persons who have previously had immune thrombocytopenic purpura, particularly for those who had thrombocytopenic purpura after an earlier dose of MMR vaccine.
Measles inclusion body encephalitis has been documented after measles vaccination in persons with immune deficiencies. The illness is also known to occur within 1 year after initial infection with wild-type measles virus and has a high death rate.
In the cases after MMR vaccination, the time from vaccination to development of measles inclusion body encephalitis was 4—9 months, consistent with development of measles inclusion body encephalitis after infection with wild-type measles virus.
Two postlicensure studies indicated that one additional febrile seizure per 2, to 2, children age 12 through 23 months occurred 5 to 12 days after the first dose of MMRV vaccine, compared with children who had received the first dose of MMR vaccine and VAR vaccine administered as separate injections at the same visit.
Data from postlicensure studies do not suggest that this increased risk exists for children age 4 to 6 years receiving the second dose of MMRV vaccine. For information on guidance for state and local health department staff who are involved in surveillance activities for vaccine-preventable diseases, please consult the Manual for the Surveillance of Vaccine-Preventable Diseases. The editors would like to acknowledge Zaney Leroy, Ginger Redmon, and Greg Wallace for their contributions to this chapter.
American Academy of Pediatrics. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR ;50 No. RR :1— Immunization of health-care personnel. Notice to readers. Revised ACIP recommendations for avoiding pregnancy after receiving rubella-containing vaccine. MMWR ;50 49 Prevention of measles, rubella, congenital rubella syndrome, and mumps, summary recommendations of the Advisory Committee on Immunization Practices ACIP.
MMWR ;62 No. To the best of our knowledge, this study is the first report demonstrating that the rubella virus infection occurred via systemic organs of the human body.
Importantly, virus infection of the ciliary body could play an important role in cataractogenesis. Official Journal of the European Union ; Studies of the natural history and prevention of rubella. Am J Dis Child ; 4 Outcome of rubella during pregnancy with special reference to the 17thth weeks of gestation. Scand J Infect Dis ; 15 4 Rubella in an immunized island population.
JAMA ; 9 Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet ; 2 Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets.
Bull World Health Organ ; 86 2 Peckham C. Congenital rubella in the United Kingdom before the prevaccine era. Rubella vaccine. Saunders; Evidence base of incubation periods, periods of infectiousness and exclusion policies for the control of communicable diseases in schools and preschools. Pediatr Infect Dis J ; 20 4 Immunisation against infectious disease.
Stationary Office Department Of Health; Factsheet Infographic. Cases of clinical measles have been documented in persons who had secondary vaccine failure.
The twentieth century saw the introduction of several successful vaccines, including those against Diphtheria, Measles, Mumps, Rubella, Influenza, Hepatitis B, and yellow fever that saved millions of lives worldwide in addition to the eradication of smallpox. Due to the excellent safety record of MV live vaccines they were employed in many labs to understand the molecular mechanisms of paramyxovirus infection. However, the research in this field was lagging due to the lack of essential tools to understand, attenuation, intracellular transport and assembly as well as pathogenesis.
The development of reverse genetics technologies to allow the rescue of non-segmented negative strand RNA viruses from cDNA 48 enabled: 1 insights on the genomic modification of a variety of MV isolates and the biology of these viruses; 2 insertion of marker gene sequences to allow localization of virus replication and infection; 3 develop multivalent recombinant vaccines against measles and other pathogens and, 4 engineer candidate oncolytic viruses against cancer.
One of the driving forces behind the reverse genetics of Mononegavirales was to gain better insight into the biology of this viral order. In fact site specific mutations, ORF elimination or modification within the MV genome became possible to answer the lagging questions.
The role of the long untranslated region UTR of the Fusion F or Matrix M genes on virus replication and pathogenesis were studied by genetic manipulation of the full-length MV genome. It was found that M protein regulates virus-envelope proteins sorting and budding in polarized epithelial cells 52 and the other mutant replicated efficiently in primary brain cells as well as the brains of transgenic mice susceptible to MV infection. Insertion of reading frames encoding various marker proteins is useful for monitoring the pathway of MV spread and replication in cells and in the organs of infected animals.
The green fluorescent protein GFP was extensively used as a marker gene to study progress of infection 54 - 56 and transmission of the virus through synapsis in hippocampal slice cultures. The modification of MV genome by enrichment of its genome by additional genes and the modification of its tropism was established upon proof-of-concept to determine: 1 the capacity of MV-genome to accommodate large inserts exceeding 6 kb of marker genes expressed simultaneously by the same virus GFP, LacZ, CAT ; 55 and 2 to stably express large gene inserts of other pathogens, and that the recombinant MV induces quantitative immune response against itself and the cloned gene products.
A recent study addressing this concern showed that the pre-existing antibody titers above mIU per ml of serum is inhibitory to rMV immunization and thus a higher dose to prime an immune response may be necessary. To specifically infect and destroy cancer cells was illusive for long time, however, methods to engineer viruses, with intrinsic cytolytic function, to specifically target cancer cells is now at reach. The swap of the viral envelope glycoproteins F and H by an envelope glycoprotein of a different virus VSV-G was practically efficient and the novel chimeric virus MV-VSV replicated in a variety of cells including cells lines that are not susceptible to MV, indicating a change in the tropism of MV.
In addition, the chimeric virus induced protective immunity to VSV susceptible mice. A heterologous challenge of these animals with fold lethal dose of VSV was not effective. Indeed, researchers at Mayo Clinic were able to generate various mutant-MVs that target specific cells.
This review is dedicated to the memory of my father who was a source of inspiration. In remembrance of my colleague and friend Steve Udem, for his documented input in the field of Mononegavirales reverse genetics. I would like to thank all members of my Group who contributed to the success of MV vector. National Center for Biotechnology Information , U.
Journal List Hum Vaccin Immunother v. Hum Vaccin Immunother. Published online Aug 5. Author information Article notes Copyright and License information Disclaimer.
Received Aug 4; Accepted Aug 4. This article has been cited by other articles in PMC. Abstract Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. Keywords: measles, pathogenesis, SSPE, vaccine, live viral vaccine, viral vectors, recombinant vaccines.
Introduction Measles, also known as morbilli, is an infection of the respiratory system, immune system and skin caused by measles virus MV , a paramyxovirus of the genus Morbillivirus.
Complications with pregnancy Measles remains a rare event in pregnancy in developing countries since most women of child-bearing age acquired measles at a young age. Measles Vaccine MV vaccines were prepared from live wild type strains that have been cultured under conditions that caused them to lose virulence without losing their ability to induce immunity.
Impact of vaccination Vaccination against MV has had a major impact on the epidemiology of measles. Reported measles cases according to WHO statistics. Open in a separate window. Immunogenicity of measles vaccine The vaccine is highly immunogenic when it is given in the correct dose to children of appropriate age.
Development of techniques that allow the rescue of MV from cDNA The twentieth century saw the introduction of several successful vaccines, including those against Diphtheria, Measles, Mumps, Rubella, Influenza, Hepatitis B, and yellow fever that saved millions of lives worldwide in addition to the eradication of smallpox. Insights on the genomic modification of MV and its biology One of the driving forces behind the reverse genetics of Mononegavirales was to gain better insight into the biology of this viral order.
Insertion of marker gene sequences to allow virus localization Insertion of reading frames encoding various marker proteins is useful for monitoring the pathway of MV spread and replication in cells and in the organs of infected animals. Development of multivalent recombinant and chimeric vaccine candidates The modification of MV genome by enrichment of its genome by additional genes and the modification of its tropism was established upon proof-of-concept to determine: 1 the capacity of MV-genome to accommodate large inserts exceeding 6 kb of marker genes expressed simultaneously by the same virus GFP, LacZ, CAT ; 55 and 2 to stably express large gene inserts of other pathogens, and that the recombinant MV induces quantitative immune response against itself and the cloned gene products.
Engineering of candidate oncolytic MVs against cancer To specifically infect and destroy cancer cells was illusive for long time, however, methods to engineer viruses, with intrinsic cytolytic function, to specifically target cancer cells is now at reach. Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. Acknowledgment This review is dedicated to the memory of my father who was a source of inspiration. References 1.
In: Infectious diseases of Children ; 8th edn. Mosby, St Louis,
0コメント